This week’s key IPO results spotlight Roche’s India growth, Abbott’s nutrition spin-off, Bajaj Healthcare’s strong Q2, and Moderna-Merck’s cancer vaccine breakthrough.
Dr Reddy’s tackles an Ozempic supply disruption, Sun Pharma faces bond market pressure, and Merck-Moderna advance cancer vaccine research.
The AbbVie lutikizumab trial met its Phase 3 primary endpoint in hidradenitis suppurativa, while the company prepares to explore an obesity-focused combination strategy.
Indian CDMO players are expanding complex-product manufacturing as Sai Life Sciences and OneSource Specialty Pharma target higher-value global outsourcing opportunities.
The World Health Organization says the first human Shamonda case in France is unlikely to cause wider spread or public health risks.
Vor Bio kidney drug telitacicept shows promise in preserving kidney function over two years in a Phase 3 IgA nephropathy trial.
Microsoft’s step-by-step AI outperforms doctors in complex cases, improving diagnostic accuracy while reducing unnecessary tests and healthcare costs.
Tricog strengthens ties with Sanofi and OMRON Healthcare to advance Indian cardiac innovation, expand global reach and improve access to early diagnosis.
Moderna stock slumps on cancer shot data, while Pfizer and Valneva advance Lyme vaccine prospects and malaria vaccine prices fall.
Tamil Nadu's dengue vaccine pilot will assess Qdenga's local performance, safety and delivery to inform future vaccination decisions.
.jpg)
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")
